SCHEMBL483945

SCHEMBL483945

CCOC(=O)N(CC(=O)OC)c1ccc(N2CCOCC2)c(F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
HPGD P15428 3/20 0.46
ALDH1A1 P00352 3/20 0.46
LMNA P02545 2/20 0.46
MLYCD O95822 1/20 0.45
MAPT P10636 4/20 0.43
KDM4E B2RXH2 3/20 0.43
POLB P06746 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
LDHA P00338 1/20 0.42
LDHB P07195 1/20 0.42
ALOX15 P16050 2/20 0.42
MAPK1 P28482 2/20 0.42
RAB9A P51151 2/20 0.42
TP53 P04637 1/20 0.42
TSHR P16473 1/20 0.42
HSD17B10 Q99714 1/20 0.41
MTOR P42345 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL483955 0.89 MLYCD (0.45) NPC1SMN1; SMN2HPGDALDH1A1LMNA
SCHEMBL483943 0.89 MLYCD (0.48) NPC1SMN1; SMN2HPGDALDH1A1LMNA
SCHEMBL483657 0.85 NPC1 (0.49) NPC1SMN1; SMN2HPGDALDH1A1LMNA
SCHEMBL483902 0.85 NPC1 (0.47) NPC1SMN1; SMN2HPGDALDH1A1LMNA
SCHEMBL483892 0.83 NPC1 (0.47) NPC1SMN1; SMN2HPGDALDH1A1LMNA
SCHEMBL16197693 0.83 NPC1 (0.47) NPC1SMN1; SMN2HPGDALDH1A1LMNA
SCHEMBL12645351 0.83 NPC1 (0.53) NPC1SMN1; SMN2HPGDALDH1A1LMNA
SCHEMBL16197860 0.81 NPC1 (0.45) NPC1SMN1; SMN2HPGDALDH1A1LMNA
SCHEMBL483637 0.81 NPC1 (0.45) NPC1SMN1; SMN2HPGDALDH1A1LMNA
SCHEMBL16197859 0.81 NPC1 (0.45) NPC1SMN1; SMN2HPGDALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090156806-A1 Process for the Preparation of Oxazolidinone Derivatives DIPHARMA FRANCIS S.R.I. (IT) 2009-06-18 US claimed
EP-2072505-B1 A process for the preparation of oxazolidinone derivatives DIPHARMA FRANCIS SRL (IT) 2012-02-01 EP disclosed
EP-2072505-A2 A process for the preparation of oxazolidinone derivatives Dipharma Francis S.r.l. (IT) 2009-06-24 EP disclosed
US-20090156806-A1 Process for the Preparation of Oxazolidinone Derivatives DIPHARMA FRANCIS S.R.I. (IT) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156806-A1 Process for the Preparation of Oxazolidinone Derivatives OXA1L, AAAS, MLYCD NPC1 4601/4885SMN1; SMN2 2136/4885HPGD 959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.